Organogenesis (NASDAQ:ORGO) Cut to Strong Sell at Wall Street Zen
by Kim Johansen · The Markets DailyWall Street Zen lowered shares of Organogenesis (NASDAQ:ORGO – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday,Wall Street Zen reports.
Several other research firms have also commented on ORGO. Weiss Ratings lowered shares of Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 19th. Truist Financial dropped their price objective on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Organogenesis currently has a consensus rating of “Reduce” and a consensus target price of $4.33.
View Our Latest Analysis on Organogenesis
Organogenesis Trading Up 11.5%
NASDAQ:ORGO opened at $0.91 on Friday. Organogenesis has a 1 year low of $0.73 and a 1 year high of $7.08. The stock’s 50 day simple moving average is $1.24 and its two-hundred day simple moving average is $2.29. The company has a quick ratio of 3.00, a current ratio of 3.52 and a debt-to-equity ratio of 0.07.
Organogenesis (NASDAQ:ORGO – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%. The firm had revenue of $45.46 million for the quarter, compared to the consensus estimate of $52.10 million.
Institutional Investors Weigh In On Organogenesis
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Organogenesis in the 2nd quarter worth approximately $17,616,000. Dimensional Fund Advisors LP increased its position in shares of Organogenesis by 5.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock valued at $6,851,000 after purchasing an additional 160,026 shares during the last quarter. Deutsche Bank AG bought a new position in shares of Organogenesis during the 2nd quarter valued at approximately $4,146,000. Renaissance Technologies LLC raised its holdings in Organogenesis by 30.5% during the 1st quarter. Renaissance Technologies LLC now owns 1,068,538 shares of the company’s stock valued at $2,532,000 after buying an additional 249,838 shares during the period. Finally, Bank of America Corp DE purchased a new stake in Organogenesis during the 2nd quarter valued at $1,368,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.
Organogenesis Company Profile
Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.
Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.